Pharmaceuticals
News Category
NanoViricides Raises $3.8 Million in Registered Direct Offering to Advance Antiviral Drug Development
NanoViricides secured approximately $3.8 million from a registered direct offering with an institutional investor, providing capital to advance its br...
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC Platform for Solid Tumors
VERAXA Biotech AG announced the appointment of Christoph Erkel as Chief Scientific Officer, effective immediately, to lead the development of its prop...
VERAXA Biotech Advances BiTAC(R)-TCE Development with Positive Regulatory Feedback from Germany
VERAXA Biotech received Scientific Advice from Germany's Paul-Ehrlich-Institute supporting the development strategy for its lead BiTAC(R)-TCE program,...
VERAXA Biotech Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform, Advancing Toward Clinical Development
VERAXA Biotech announced positive regulatory feedback from Germany's Paul-Ehrlich-Institute on its BiTAC-TCE platform, supporting its dual-targeting a...
Siegfried Appoints Eduardo Montanha as COO to Drive Integrated Operations Strategy
Siegfried has appointed Eduardo Montanha as Chief Operating Officer to lead its combined Drug Substances and Drug Products operations, supporting its ...
NextPlat Corp Acquires Florida Pharmacy to Expand PharmcoRx Rural Presence
NextPlat Corp's planned acquisition of an independent pharmacy near Pensacola, Florida, for $1.5 million aims to expand its PharmcoRx network into und...
Onco-Innovations Completes Analytical Reference Standard Program for ONC010, Advancing Oncology Candidate Toward Clinical Readiness
Onco-Innovations Limited has finalized its analytical reference standard for ONC010's active ingredient, strengthening its CMC framework and supportin...
VERAXA Biotech Advances Lead BiTAC T-Cell Engager Program with Cell Line Development Partnership
VERAXA Biotech has partnered with ATUM to develop stable cell lines for its lead BiTAC T-cell engager, marking a critical step toward clinical trials ...
Sustained Release Polymers Market to Reach USD 7.8 Billion by 2036 Driven by Chronic Disease Management and Drug Delivery Innovation
The sustained release polymers market is projected to grow from USD 3.8 billion in 2026 to USD 7.8 billion by 2036 at a 7.4% CAGR, driven by increasin...
VERAXA Biotech Advances BiTAC Platform, Seeks Partnerships to Fund Pipeline
VERAXA Biotech AG provided a corporate update highlighting progress in its proprietary BiTAC platform, with four T-cell engager programs targeting sol...
VERAXA Biotech Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program
VERAXA Biotech has begun cell line development for its lead BiTAC T-cell engager program in collaboration with ATUM, aiming to advance a novel cancer ...
VERAXA Biotech AG Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals
The article highlights the strong deal activity in antibody-drug conjugates and T-cell engager therapeutics, positioning VERAXA Biotech's platform as ...
Ace Therapeutics Launches Comprehensive Preclinical Analgesic Drug Development Services with Full-Spectrum Pain Research Platform
Ace Therapeutics announces end-to-end preclinical analgesic drug development services featuring diverse validated in vivo pain models and a full suite...
Medios AG Closes Aschaffenburg Facility Amid Margin Pressure, Optimizes Manufacturing Network
Medios AG is closing its Aschaffenburg facility and consolidating patient-specific manufacturing to improve efficiency, citing sustained margin pressu...
Helus Pharma Reports Fiscal 2026 Results, Phase 3 Trial for Depression Drug on Track
Helus Pharma announced fiscal 2026 financials and progress in its Phase 3 trials for HLP003 in major depressive disorder, with topline data expected i...
Voyageur Pharmaceuticals Engages Fluor to Advance Feasibility Studies for Iodine Production and Integrated Contrast Drug Manufacturing Facility
Voyageur Pharmaceuticals has hired Fluor Corporation to conduct feasibility studies for an iodine extraction facility in Oklahoma and an integrated co...
Knight Therapeutics Repays $60 Million Credit Facility Used for Paladin Acquisition
Knight Therapeutics has fully repaid its revolving credit facility drawn to finance the Paladin acquisition, using operational cash flow, while mainta...
Voyageur Pharmaceuticals Evaluates Three U.S. Sites for Integrated Iodine and Barium Contrast Media Manufacturing Facility
Voyageur Pharmaceuticals is evaluating three U.S. sites for a vertically integrated contrast media manufacturing facility, aiming to reduce costs and ...
Earth Science Tech Inc. Builds Vertically Integrated Telehealth and Pharmacy Ecosystem
Earth Science Tech Inc. (ETST) is transforming into a diversified holding company with a new telemedicine platform and pharmacy operations, emphasizin...
Voyageur Pharmaceuticals Submits Multi-Year Permit Application for Frances Creek Barite Project, Advancing Toward Feasibility Study
Voyageur Pharmaceuticals has submitted a multi-year exploration permit application for its Frances Creek barite project, enabling a test extraction of...
Voyageur Pharmaceuticals Closes $5 Million Private Placement for Contrast Media Development
Voyageur Pharmaceuticals closed a $5 million private placement to fund FDA licensing, regulatory approvals, and project development for its barium and...
Kairos Pharma Mid-Year Update Highlights Pipeline Expansion and Clinical Milestones
Kairos Pharma's mid-year 2026 update details plans to acquire a Phase 1-ready oral c-MET inhibitor to expand its oncology pipeline and advance clinica...
Quantum BioPharma Highlights Lucid-MS and unbuzzd Growth Opportunities on BioMedWire Podcast
Quantum BioPharma's lead drug candidate Lucid-MS aims to address mobility loss in multiple sclerosis by targeting nerve damage, while its commercial p...
Quantum BioPharma's Multiple Sclerosis Program Advances to IND Submission Stage
Quantum BioPharma Ltd. progresses its clinical-stage multiple sclerosis program toward Phase 2 trials, supported by a diversified portfolio spanning t...
Redwood AI Corp. Gains DTC Eligibility and Engages IBN for Investor Awareness
Redwood AI Corp. announced DTC eligibility for its common shares and a $114,000 engagement with InvestorBrandNetwork for market awareness services, ai...
Carmed Pharmaceuticals Leverages CityBiz Feature to Boost U.S. Expansion
Carmed Pharmaceuticals, a Turkey-based maker of standardized carvacrol-based formulations, is advancing its U.S. market entry through a CityBiz Q&A wi...
Sino Biological Launches XPressMAX™ Cell-Free Protein Synthesis Kit to Accelerate AI-Powered Antibody Discovery
Sino Biological's new XPressMAX™ Cell-Free Protein Synthesis Kit enables ultra-fast protein synthesis in three hours, supporting AI-driven high-throug...
NanoViricides Advances NV-387 Toward Phase II Clinical Trials for MPox in Democratic Republic of Congo
NanoViricides reported progress on its broad-spectrum antiviral NV-387, including regulatory approval for Phase II MPox trials in the DRC and FDA orph...
NanoViricides Prices $2 Million Registered Direct Offering
NanoViricides announced a $2 million registered direct offering with a single institutional investor, issuing common shares and warrants, to fund its ...
Lantern Pharma Raises $4.4 Million in Registered Direct Offering to Advance AI-Driven Oncology Pipeline
Lantern Pharma closed a $4.4 million registered direct offering, with potential additional proceeds from warrants, to support its AI-powered precision...
Tonix Pharmaceuticals to Present at Two Investor Conferences in May
Tonix Pharmaceuticals (NASDAQ: TNXP) will showcase its CNS and immunology pipeline at the RBC Capital Markets Global Healthcare Conference and A.G.P.’...
Lantern Pharma Expands predictBBB Platform Into Large Quantitative Model for Drug Discovery
Lantern Pharma has expanded its predictBBB platform into a Large Quantitative Model, offering researchers a real-time molecular intelligence engine fo...
LIXTE Biotechnology's LB-100 Aims to Enhance Chemotherapy and Immunotherapy Effectiveness
LIXTE Biotechnology Holdings is advancing LB-100, a first-in-class PP2A inhibitor, as a novel approach to make tumors more responsive to existing canc...
Soligenix Pioneers Platform-Based Drug Development with Synthetic Hypericin Across Multiple Indications
Soligenix exemplifies efficient drug development by leveraging its synthetic hypericin platform for both cutaneous T-cell lymphoma and psoriasis, redu...
PolyPeptide Shareholders Approve All Proposals at Annual General Meeting 2026
PolyPeptide Group AG announced that shareholders approved all board proposals at its fifth annual general meeting, including re-election of directors ...
LIXTE Biotechnology Holdings Files 2025 Form 10-K, Highlights Transformational Year with Clinical and Strategic Advances
LIXTE Biotechnology Holdings filed its 2025 annual report, detailing leadership changes, expanded clinical trials for its lead compound LB-100, the ac...
LIXTE Biotechnology's LB-100: The World's Only Clinical-Stage PP2A Inhibitor Poised to Transform Cancer Treatment
LIXTE Biotechnology's lead compound LB-100, the only clinical-stage PP2A inhibitor, enhances cancer cell sensitivity to therapy and disrupts DNA repai...
Lonza Nominates Stephen Fry as Independent Board Member
Lonza nominates former Eli Lilly executive Stephen Fry to its board, bringing expertise in organizational transformation and performance culture to su...
Voyageur Pharmaceuticals Progresses Barium and Iodine Contrast Media Projects, Targeting North American Supply Chain Security
Voyageur Pharmaceuticals advances bankable feasibility studies for barium and iodine contrast media production, aiming to establish a vertically integ...
Soligenix Secures European Milestone for Dusquetide in Behçet's Disease
Soligenix received a positive EMA opinion for orphan drug designation of dusquetide for Behçet's disease, unlocking development incentives and potenti...
Netherton Now Campaign Surpasses 2 Million Video Views, Raising Global Awareness for Rare Genetic Disease
Quoin Pharmaceuticals' Netherton Now awareness campaign has garnered nearly 2 million video views and over 24 million impressions, highlighting the ur...
Oncotelic Therapeutics Featured in BioMedWire Editorial on Late-Stage Biotech M&A Trends
Oncotelic Therapeutics' inclusion in a BioMedWire editorial highlights the growing M&A focus on de-risked late-stage oncology and CNS assets, position...
Helus Pharma Phase 2a Trial Shows SPL026 Significantly Reduces Depressive Symptoms in Major Depressive Disorder
Helus Pharma announced positive Phase 2a results for SPL026, published in Nature Medicine, demonstrating significant and clinically meaningful reducti...
BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer
BioVaxys announced positive Phase 2 results for its immunotherapy MVP-S combined with pembrolizumab and low-dose cyclophosphamide in metastatic bladde...